Vancomycin + Daptomycin + Semi-Synthetic Penicillin
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Complicated Skin and Skin Structure Infections
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Trial Timeline
Apr 19, 2010 → Jun 12, 2012
NCT ID
NCT01104662About Vancomycin + Daptomycin + Semi-Synthetic Penicillin
Vancomycin + Daptomycin + Semi-Synthetic Penicillin is a approved stage product being developed by Merck for Complicated Skin and Skin Structure Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT01104662. Target conditions include Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01104662 | Approved | Terminated |
Competing Products
20 competing products in Complicated Skin and Skin Structure Infections